Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
This disclosure relates to a GM-CSF and IL-4 conjugate fused to a glycolipid (GPI)-anchoring sequence that is incorporated into chimeric virus-like particles (VLPs) enriched with a viral protein, e.g., viral envelope protein or HIV envelope protein. In certain embodiments, the disclosure relates to methods of immunization with the chimeric VLPs disclosed herein. In certain embodiments, the disclosure relates to methods of immunization with disclosed HIV antigen containing VLPs through an intramuscular priming-intranasal boosting immunization route.
1. A nucleic acid encoding a fusion protein comprising the amino acid sequence of SEQ ID NO: 7.
2. A vector comprising the nucleic acid of claim 1 in operable combination with a promoter sequence.
3. An in vitro cell comprising the vector of claim 2 .
4. A chimeric virus-like particle comprising the fusion protein encoded by the nucleic of claim 1 .
5. The chimeric virus-like particle of claim 4 , further comprising a viral envelope protein.
6. The chimeric virus-like particle of claim 5 , wherein the viral envelope protein is an HIV envelope protein.
7. The chimeric virus-like particle of claim 6 , wherein the viral envelope is gp160, gp120, or gp41.
8. An in vitro cell comprising the nucleic acid of claim 1 .
9. A nucleic acid encoding a fusion protein comprising a variant amino acid sequence of SEQ ID NO: 7, wherein the variant comprises one conserved amino acid substitution.
10. A vector comprising the nucleic acid of claim 9 in operable combination with a promoter sequence.
11. An in vitro cell comprising the vector of claim 10 .
12. A chimeric virus-like particle comprising the fusion protein encoded by the nucleic of claim 9 .
13. The chimeric virus-like particle of claim 12 , further comprising a viral envelope protein.
14. The chimeric virus-like particle of claim 13 , wherein the viral envelope protein is an HIV envelope protein.
15. The chimeric virus-like particle of claim 14 , wherein the viral envelope is gp160, gp120, or gp41.
16. An in vitro cell comprising the nucleic acid of claim 9 .